New test to study proteins involved in neurodegenerative diseases

Feb 01, 2011

Researchers from the Institute of Biotechnology and Biomedicine and the UAB Department of Biochemistry and Molecular Biology (Spain) have developed and patented a method using Saccharomyces cerevisiae yeast to detect in human proteins the formation of oligomers, small toxic aggregations of molecules which can initiate the assembly of amyloid fibres found in neurodegenerative diseases. The test allows validating the efficacy of compounds which could dissolve or inhibit these aggregates, as well as studying at basic level the therapeutic potentiality of a large number of molecules.

Oligomers are formed by the union of two to twenty molecules. Recent research studies seem to indicate that their toxicity is higher than that of amyloid fibres. However, studying these substances is not easy given that they are unstable and their formations are transitory.

The method developed by researchers at UAB locates and monitors in vivo the aggregation process of the protein using fluorescence techniques and without the need to resort to alternative methods. It also allows studying compounds which inhibit oligomers as potentially therapeutic mechanisms to prevent posterior formations of .

The screening system was carried out by genetically modifying Saccharomyces cerevisiae to link human protein aggregation to . It is based on the fusion of the human peptide under study with the human variant of a protein needed for the survival of the modified yeast, dihydrofolate reductase (DHFR). The aggregation of the peptide deactivates the DHFR protein and finally produces the death of the cell, thereby providing a detection system of molecules with tendency to aggregate and in which any compound capable of separating or inhibiting this aggregation would favour the survival of the cell.

Researchers carried out the study with the AB42 peptide, the main cause of Alzheimer's disease. To validate the test they worked with several compounds in vitro which, in studies related to the disease, had demonstrated to be effective against the formation of oligomers, amyloid fibres or both types of molecules. The system only showed to be effective with compounds affecting oligomers, which makes it a very specific method for the initial detection of the aggregation process. The system was also validated with chaperones, a group of proteins which increase the dissolution of protein aggregation and favour cell survival. In addition to AB42, researchers validated the assay with regard to the detection of initial aggregations, by using proteins involved in Parkinson's and Huntington's disease.

According to Salvador Ventura, one of the authors of the study, the system is easy to use and allows scientists to work quickly and to analyse with reliability the potential therapeutic efficacy of an infinite number of compounds at experimental level. Now there is the need to automate the system - with plates allowing for the simultaneous analysis of more than fifty per assay - to be used in basic research. For the moment the system has been patented by the researchers.

Explore further: Vegetable oil ingredient key to destroying gastric disease bacteria

Provided by Universitat Autonoma de Barcelona

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Yeast model shows promise as Alzheimer's test

Nov 18, 2006

A century ago this month, German psychiatrist Alois Alzheimer formally described characteristics of the neurodegenerative disease which ultimately came to bear his name. While international efforts to learn about Alzheimer's ...

Research reveals early steps in Parkinson's pathology

Apr 06, 2010

Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press ...

Alzheimer's research yields potential drug target

Jul 01, 2009

Scientists at UC Santa Barbara and several other institutions have found laboratory evidence that a cluster of peptides may be the toxic agent in Alzheimer's disease. Scientists say the discovery may lead ...

Unfolding amyloid secrets

Jan 20, 2011

Scientists from the University of Leeds have made a fundamental step in the search for therapies for amyloid-related diseases such as Alzheimer's, Parkinson's and diabetes mellitus. By pin-pointing the reaction that kick-starts ...

Recommended for you

A hybrid vehicle that delivers DNA

23 hours ago

A new hybrid vehicle is under development. Its performance isn't measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.